#United States #San Francisco #Securities Fraud #Hagens Berman #Aardvark Therapeutics

Overview of Aardvark Therapeutics Case

Aardvark Therapeutics, Inc. (NASDAQ: AARD), a biopharmaceutical company, finds itself under scrutiny as a class action lawsuit has been filed due to claims of securities fraud. Investors who acquired stocks from Aardvark during the initial public offering (IPO) on February 13, 2025, or those who bought shares up until May 14, 2026, are being notified by Hagens Berman Sobol Shapiro LLP, a prominent national shareholder rights law firm. The lawsuit primarily revolves around allegations of misleading statements regarding the safety and efficacy of Aardvark's drug candidate, ARD-101,

targeting treatments for hyperphagia in Prader-Willi Syndrome (PWS).

Key Case Details

The class action lawsuit has outlined serious concerns regarding ARD-101's safety profile. Specifically, it has been claimed that Aardvark provided false information regarding the drug's safety and failed to disclose critical adverse findings that emerged during clinical trials. Notable issues included unexpected cardiac events that occurred in trials conducted at high dosage levels. Concerns were raised about the true clinical and commercial potential of the therapy, especially in light of recent findings, which have led to a significant decline in stock prices.

Timeline of Events

• - February 2026: Aardvark announced a voluntary pause in the Phase 3 HERO trial due to observed cardiac effects during safety monitoring. This announcement led to a drastic over 56% drop in the company's stock price.
• - May 2026: Further complications arose when the FDA imposed a full clinical hold on the IND for ARD-101. All ongoing clinical studies related to the therapy were halted. Following this news, Aardvark's stock lost an additional 32.1% of its value.

The Allegations

The lawsuit contends that Aardvark was aware of the safety concerns regarding ARD-101 but failed to maintain transparency with investors. The lack of disclosure about these critical issues has resulted in investors suffering significant financial losses. Legal representatives believe that the exaggerated claims surrounding ARD-101’s safety can be categorized as egregious misconduct, potentially uncovering a wider trend of corporate negligence in biomedical firms.

What Investors Should Do

Investors who have sustained losses from investments in Aardvark are encouraged to reach out to Hagens Berman before the lead plaintiff deadline on October 13, 2026. Participating investors have an opportunity to seek restitution by requesting the court to appoint them as lead plaintiff for the class action.

Whistleblower Opportunities

Individuals who possess insider knowledge about Aardvark Therapeutics and wish to report on the matter may also have options available under the SEC Whistleblower program. Rewarding individuals up to 30% of any recovery achieved by the SEC, this program is designed to encourage transparency and accountability in corporate governance.

Conclusion

As Aardvark Therapeutics navigates this challenging phase, affected investors must take proactive steps to understand their rights and weigh their options under the law. The allegations of securities fraud, combined with the downward spiral of stock performance, have created a pivotal moment for stakeholders involved with Aardvark. For detailed information, investors can visit Hagens Berman’s dedicated webpage for the Aardvark case or contact them directly through their website.